Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Tonix Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Read about Tonix Pharmaceuticals Holding Corp (TNXP:XNAS) stock and today's latest news and financial updates.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Tonix Pharmaceuticals Holding Corp.'s TNX-102 SL faces an FDA decision by August 2025. Click here to read an analysis of TNXP stock update.

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered ...

Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and ...

Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...